Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
FOSTER CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today reported financial results for the quarter ended September 30, 2026, and provided corporate updates.
Covered in this story
Analyst targets on Sagimet Biosciences
- Citizens JMP: at $9.37 · target $27 by Oct 2027 · Market Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $SGMT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Sagimet Biosciences →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.